Given the findings in CeD and DH, it is tempting to suggest that enzyme-activating BCRs in RA might boost interactions between PAD4-specific B cells and citrulline-specific CD4+ T cells. The gene discussed is CD4; the disease is cranioectodermal dysplasia.